Lingchao Meng

Lingchao Meng


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2021 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
KDKang Du
Kang Du
FLFan Li
Fan Li
HWHui Wang
Hui Wang
YMYuanfeng Miao
Yuanfeng Miao
HLHe Lv
He Lv
LMLingchao Meng
Lingchao Meng
Objective: This study aims to report the genotypes and phenotypes of hereditary transthyretin amyloidosis (ATTR) in a large Chinese cohort, yet the clinical and genetic profiles of ATTR remain elusive in mainland China.Methods: Fifty‐four patients with molecularly confirmed ATTR from 39 unrelated families were identified by sequencing the TTR gene. Sural nerve biopsies were performed in 40 of these cases. The clinical and electrophysiological data were retrospectively collected and analyzed.Results: The male/female ratio was 42:12. The average age of patients at the onset of the disease was 47.8 ± 13.0 years. The late‐onset type occurred in 29 cases (53.7%). Twenty‐two probands (56.4%) had a family history with ATTR. The initial symptoms were limb paresthesia in 33 cases (61.1%), autonomic dysfunction in 15 cases (27.8%), and blurred vision in 6 cases (11.1%). A total of 22 different TTR mutations were identified, including Val30Met (25.6%) in 10 families in North China and Ala97Ser in 4 families (10.3%) in South China. Electrophysiological studies revealed general sensorimotor axonal polyneuropathy in 33/44 cases (75.0%), mixed neuropathy with axonal and demyelinating impairment features in 9/44 cases (20.5%) and isolated carpal tunnel syndrome in two cases. Sural nerve biopsies revealed positive Congo red staining in 16/40 cases (40.0%).Conclusion: Chinese patients with ATTR exhibited heterogeneous TTR genotypes and clinical phenotypes. Val30Met remains the most common mutation type in mainland China.

26 September 2024 in European Journal of Neurology
Verified
Journal Article
Open access
JLJieyu Li
Jieyu Li
CGChao Gao
Chao Gao
QWQingqing Wang
Qingqing Wang
JLJing Liu
Jing Liu
ZXZhiying Xie
Zhiying Xie
ZWZhaoxia Wang
Zhaoxia Wang
Background and Purpose: The substantial role of inflammation in amyotrophic lateral sclerosis (ALS) is gaining support from recent research. Studies indicate that circulating cell‐free mitochondrial DNA (ccf‐mtDNA) can activate the immune system and is associated with neurodegenerative diseases. This research was designed to quantify ccf‐mtDNA levels in the serum of ALS patients.Methods: The medical records of ALS patients were reviewed. Serum ccf‐mtDNA levels of patients with ALS (n = 62) and age‐matched healthy controls (n = 46) were measured and compared. Additionally, serum interleukin‐6 (IL‐6) levels were measured using an enzyme‐linked immunosorbent assay in 26 ALS patients. Correlations between variables were analyzed.Results: Serum ccf‐mtDNA was notably higher in the patients with ALS. When stratified by genotype, the superoxide dismutase 1 (SOD1) mutation group showed the greatest increase in ccf‐mtDNA levels relative to other ALS patients. Among all 108 individuals, a cut‐off set at 1.1 × 105 mtDNA copies on a receiver‐operating characteristic curve identified patients with ALS with 80.7% sensitivity and 50.0% specificity; the area under the curve was 0.69 (p < 0.001). Furthermore, serum ccf‐mtDNA levels correlated negatively with the progression rate of ALS (ΔFS; rs = −0.26, p = 0.044), but not the ALSFRS‐R score (rs = 0.06, p = 0.625). Importantly, the correlation between ccf‐mtDNA and ΔFS was more pronounced in the SOD1 mutation group (rs = −0.62, p = 0.018). Lastly, a significant positive association was observed between serum ccf‐mtDNA levels and IL‐6 levels in ALS (r s= 0.41, p = 0.038).Conclusion: Our study found increased serum ccf‐mtDNA in ALS patients, suggesting a link to inflammatory processes and disease mechanism. Moreover, ccf‐mtDNA could be an indicator for ALS progression, especially in those with the SOD1 mutation.

17 March 2023 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
YTYuwei Tang
Yuwei Tang
JLJing Liu
Jing Liu
FGFeng Gao
Feng Gao
HHHongjun Hao
Hongjun Hao
ZJZhirong Jia
Zhirong Jia
ZWZhaoxia Wang
Zhaoxia Wang
Objective: The co‐morbidity of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)/autoimmune nodopathies with nephropathy has been gradually known in recent years. This study was intended to explore the clinical, serological and neuropathological features of seven patients with CIDP/autoimmune nodopathies and nephropathy.Methods: Among 83 CIDP patients, seven were identified with nephropathy. Their clinical, electrophysiological and laboratory examination data were collected. The nodal/paranodal antibodies were tested. The sural biopsies were performed in all the patients, and renal biopsies were operated in 6 patients.Results: Six patients had chronic onsets and one had an acute onset. Four patients exhibited peripheral neuropathy preceding nephropathy while two showed concurrent onset of neuropathy and nephropathy, and one started with nephropathy. All the patients showed demyelination in electrophysiological examination. Nerve biopsies showed mild to moderate mixed neuropathies including demyelinating and axonal changes in all patients. Renal biopsies showed membranous nephropathy in all 6 patients. Immunotherapy was effective in all patients, with two patients showing good response to corticosteroid treatment alone. Four of the patients were positive to anti‐CNTN1 antibody. Compared with anti‐CNTN1 antibody‐negative patients, antibody‐positive patients had a higher proportion of ataxia (3/4 vs. 1/3), autonomic dysfunction (3/4 vs. 1/3), less frequent antecedent infections (1/4 vs. 2/3), higher cerebrospinal fluid proteins (3.2 g/L vs. 1.69 g/L), more frequent conduction block on electrophysiological examination (3/4 vs. 1/3), higher myelinated nerve fiber density, and positive CNTN1 expression in the glomeruli of kidney tissues.Conclusion: Anti‐CNTN1 antibody was the most frequent antibody in this group of patients with CIDP/autoimmune nodopathies and nephropathy. Our study suggested that there might be some clinical and pathological differences between the antibody positive and negative patients.

29 December 2021 in Journal of Neuroimaging
Verified
Journal Article
Open access
PDF file
KDKang Du
Kang Du
KXKe Xu
Ke Xu
XCXujun Chu
Xujun Chu
YTYuwei Tang
Yuwei Tang
HLHe Lv
He Lv
LMLingchao Meng
Lingchao Meng
Background and Purpose: Autonomic dysfunction is common in transthyretin familial amyloid polyneuropathy (TTR‐FAP). Because ultrasonography is a powerful tool to study peripheral neuropathy, vagus nerve (VN) ultrasonography was used in our study to investigate the possible changes of the dimension of VN in TTR‐FAP.Methods: Eighteen patients with TTR‐FAP and 17 age‐ and gender‐matched individuals without any neuropathies were enrolled in a pilot study. The cross‐sectional areas (CSAs) were measured bilaterally on transverse scans of vagus, median, and ulnar nerves. Clinical data were collected to explore the correlations with CSAs of VN.Results: The median CSAs of VN in TTR‐FAP were 3.5 (2.0‐6.0) mm2 on the right side and 2.5 (1.0‐6.0) mm2 on the left side, compared with 2.0 (1.0‐3.0) mm2 and 1.0 (1.0‐2.0) mm2 for healthy controls (HCs). There was a significant difference between the two groups on both sides (p < .001). The mean VN CSAs were correlated positively with the course of disease (r = .7203, p = .0016)(not including the patient with the longest disease course), the Composite Autonomic Symptom Score 31 (r = .5252, p = .0252), the left ventricular posterior wall thickness (r = .5426, p = .0200), and the interventricular septum thickness (r = .5103, p = .0305). The cutoff values of right and left VN CSAs to identify TTR‐FAP from HCs were 2.5 and 1.5 mm2 and the areas under the curve were .9395 and .8856, with a high sensitivity (.889 and .889) and specificity (.941 and .765), respectively.Conclusion: VN enlargement is prevalent among TTR‐FAP patients. VN ultrasonography may be an important clinical tool for assessing the severity of autonomic dysfunction in TTR‐FAP.

20 February 2025 in Annals of Neurology
Verified
Journal Article
Closed access
XCXujun Chu
Xujun Chu
JKJuan Kang
Juan Kang
JXJingwen Xu
Jingwen Xu
HJHaishan Jiang
Haishan Jiang
Zhi-Ying WuZhi-Ying Wu
Zhi-Ying Wu
LMLingchao Meng
Lingchao Meng

10 October 2020 in Genes
Verified
Journal Article
Open access
PDF file
ZXZhiying Xie
Zhiying Xie
LTLiuqin Tang
Liuqin Tang
ZXZhihao Xie
Zhihao Xie
CSChengyue Sun
Chengyue Sun
HSHaoyue Shuai
Haoyue Shuai
YYYun Yuan
Yun Yuan
Pseudoexon (PE) inclusion has been implicated in various dystrophinopathies; however, its splicing characteristics have not been fully investigated. This study aims to analyze the splicing characteristics of dystrophin PEs and compare them with those of dystrophin canonical exons (CEs). Forty-two reported dystrophin PEs were divided into a splice site (ss) group and a splicing regulatory element (SRE) group. Five dystrophin PEs with characteristics of poison exons were identified and categorized as the possible poison exon group. The comparative analysis of each essential splicing signal among different groups of dystrophin PEs and dystrophin CEs revealed that the possible poison exon group had a stronger 3′ ss compared to any other group. As for auxiliary SREs, different groups of dystrophin PEs were found to have a smaller density of diverse types of exonic splicing enhancers and a higher density of several types of exonic splicing silencers compared to dystrophin CEs. In addition, the possible poison exon group had a smaller density of 3′ ss intronic splicing silencers compared to dystrophin CEs. To our knowledge, our findings indicate for the first time that poison exons might exist in DMD (the dystrophin gene) and present with different splicing characteristics than other dystrophin PEs and CEs.